實(shí)驗(yàn)要點(diǎn)及說明：

1．本方法適用于貼壁細(xì)胞培養(yǎng)，而不適用于懸浮細(xì)胞培養(yǎng)，懸浮細(xì)胞可使用滴片法； 

2．所使用的蓋玻片應(yīng)該為玻璃**，并經(jīng)過鉻酸洗液處理； 

3．蓋玻片非常薄，易碎，取放蓋玻片時(shí)動(dòng)作要輕； 

4．如果需要更多生長狀態(tài)一致的細(xì)胞，可以使用較大的培養(yǎng)皿，但不宜過大，以避免培養(yǎng)液的浪費(fèi)和增加污染機(jī)率； 

5．如果細(xì)胞貼壁生長能力較差，可將蓋玻片在0.5%多聚賴氨酸溶液中浸泡5-10分鐘并自然晾干。

培養(yǎng)方法

傳代方法 將舊培養(yǎng)液吸除，PBS清洗兩遍后，加入6mL（/100mm皿）胰酶，在顯微鏡下觀察，期間禁止搖晃培養(yǎng)皿，細(xì)胞剛有脫落時(shí)，則吸除大部分胰酶，留約0.5mL，移至培養(yǎng)箱消化，約2min取出。傳代用12mL CM1-1培養(yǎng)液終止消化，輕輕吹打均勻細(xì)胞，后可分3~6皿培養(yǎng)；

生長條件 37℃，5%CO2，CM1-1培養(yǎng)液。CM1-1培養(yǎng)液：90%DMEM-H+10%FBS。DMEM-H：DMEM高糖培養(yǎng)液，含谷氨酰胺，含丙酮酸鈉。

存儲(chǔ)條件 凍存則用6mL凍存液（90%FBS+10%DMSO）終止消化，吹打均勻，分為6支凍存管，用程序降溫盒于-80℃凍存，過夜轉(zhuǎn)移至液氮中保存。

我司常期代理ATCC Acris  abcam  cst  Biorbyt  santa  Novus  sigma  lifespan  NEB  roche  ABI  R&D millipore   BD  Qiagen Cayman  Jackson Life  GeneTex   Bio-Rad DSHB  tocris   peprotech 等品牌；部分產(chǎn)品現(xiàn)貨，超低比價(jià)，貨期短，價(jià)格優(yōu)，公司產(chǎn)品僅用于科研售后齊全。

培養(yǎng)操作步驟 ：

1．用蓋片鑷將蓋玻片自75%乙醇中取出，用無菌絲綢布擦拭干凈，不要用紗布； 

2．將蓋玻片輕輕放入6孔培養(yǎng)板（每孔一片）或培養(yǎng)皿中（每個(gè)平皿可放置2-3片）； 

3．在距離紫外燈直射范圍內(nèi)20-30 厘米處照射2-3小時(shí)； 

4．將經(jīng)過計(jì)數(shù)的細(xì)胞懸浮液移入培養(yǎng)板中，使蓋玻片完全浸在培養(yǎng)液中； 

5．將培養(yǎng)板在5% CO2水浴孵箱中37℃孵育2-3天，當(dāng)貼壁細(xì)胞生長至覆蓋培養(yǎng)板底部2/3面積時(shí)，將培養(yǎng)板取出，用蓋片鑷輕輕取出蓋玻片，用蒸餾水漂洗后即可進(jìn)行快速固定以及細(xì)胞化學(xué)檢測。 

細(xì)胞培養(yǎng)方法：

1、細(xì)胞傳代：細(xì)胞密度達(dá)到80-90%時(shí)即可傳代

①棄去培養(yǎng)上清，用PBS或生理鹽水清洗1-2次；

②加入2ml0.25%胰酶（T25瓶），使胰酶覆蓋整個(gè)瓶或皿，蓋好放入培養(yǎng)箱消化；

③1-2min后，顯微鏡下觀察細(xì)胞，若大部分細(xì)胞回縮且有少量細(xì)胞脫落，輕輕吹打下確認(rèn)消化情況后加入完全培養(yǎng)基終止消化；若細(xì)胞還是貼壁，放回培養(yǎng)箱繼續(xù)消化至可以輕輕吹打下為止；

④將細(xì)胞懸液1000RPM左右條件下離心4min，棄上清；

⑤用新鮮培養(yǎng)基重懸后加入培養(yǎng)瓶或皿中，T25培養(yǎng)瓶加6-8ml培養(yǎng)基；

⑥懸浮細(xì)胞直接離心收集，細(xì)胞沉淀重懸后分到新培養(yǎng)瓶中。

2、細(xì)胞復(fù)蘇：

①將凍存管在37℃溫水中快速搖晃融化，時(shí)間1min左右，加入4-5ml培養(yǎng)基混勻。

②在1000RPM左右條件下離心4min，棄上清,加1-2ml培養(yǎng)基吹勻，將細(xì)胞懸液加入培養(yǎng)瓶中，補(bǔ)加適量培養(yǎng)基。

3、細(xì)胞凍存：待細(xì)胞生長狀態(tài)良好時(shí)進(jìn)行細(xì)胞凍存保種

①棄去培養(yǎng)上清，用PBS或生理鹽水清洗1-2次，加入1mL 0.25%胰蛋白酶（T25瓶）

②1-2min后，顯微鏡下觀察細(xì)胞，大部分細(xì)胞回縮且有少量細(xì)胞脫落，輕輕吹打下確認(rèn)消化情況后加入完全培養(yǎng)基終止消化；

③將細(xì)胞懸液1000RPM左右條件下離心4min，棄上清，加1ml凍存液重懸細(xì)胞；

④將凍存管放入程序降溫盒，放入-80℃冰箱，4小時(shí)后將凍存管轉(zhuǎn)入液氮罐儲(chǔ)存。

Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.

Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.

Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease. [DISEASE] Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.

Defects in MAPT are a cause of Parkinson-dementia syndrome (PARDE) [MIM:260540]. A syndrome characterized by parkinsonism tremor, rigidity, dementia, ophthalmoparesis and pyramidal signs. Neurofibrillary degeneration occurs in the hippocampus, basal ganglia and brainstem nuclei.

Similarity : Contains 4 Tau/MAP repeats.

Database links : UniProtKB/Swiss-Prot: P10636.5

PHF以神經(jīng)原纖維纏結(jié)(neurofibrillary tangles, NFT)存在于神經(jīng)元的胞體;以神經(jīng)毯和神經(jīng)炎性斑存在于受累神經(jīng)元的退化樹突.微管相關(guān)蛋白tau是PHF的主要組成成分.在AD腦中,特別是在PHF結(jié)構(gòu)中的tau被異常過度磷酸化.用磷酸化依賴的特異抗tau抗體檢測,已證明PHF中的tau蛋白至少有21個(gè)異常磷酸化位點(diǎn).

英文名稱  Anti-PHYH

中文名稱  植烷酸氧化酶抗體

別    名  LN1; PAHX; PhyH; PHYH1; Phytanic acid oxidase; phytanoyl CoA 2 hydroxylase; Phytanoyl CoA 2 oxoglutarate dioxygenase; Phytanoyl CoA alpha hydroxylase; Phytanoyl CoA dioxygenase; RD antibody.

濃    度  1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來源  Rabbit  

克隆類型  polyclonal

交叉反應(yīng)  Human, Mouse, Rat, Dog, Cow, Rabbit

產(chǎn)品類型  一抗    

研究領(lǐng)域  腫瘤 細(xì)胞生物 學(xué) 神經(jīng)生物學(xué) 轉(zhuǎn)錄調(diào)節(jié)因子  

蛋白分子量  predicted molecular weight: 38kDa
原代巨噬細(xì)胞培養(yǎng)體系蛋白精氨酸甲基轉(zhuǎn)移酶1檢測試劑盒反-氯丹 分析標(biāo)準(zhǔn)品氯T 三水合物 CP,98%

二甲基精氨酸二水解酶1檢測試劑盒二基錫 分析標(biāo)準(zhǔn)品氯T 三水合物 ACS, 98%

二甲基精氨酸二水解酶2檢測試劑盒二庚基錫 分析標(biāo)準(zhǔn)品氯T 三水合物 AR,99.0%

二甲基精氨酸二水解酶1檢測試劑盒倍硫磷 分析標(biāo)準(zhǔn)品溴乙酰二甲縮, 含0.2 % 碳酸穩(wěn)定劑, 97%

二甲基精氨酸二水解酶2檢測試劑盒倍硫磷標(biāo)準(zhǔn)溶液 1.00mg/ml乙酸鎂,四水 AR ,99.0%

中性粒趨化因子檢測試劑盒倍硫磷標(biāo)準(zhǔn)溶液 100μg/ml,u=4%硫酸鎂，七水 AR,99.0%

甲狀旁腺檢測試劑盒倍硫磷標(biāo)準(zhǔn)溶液 10μg/ml,u=6%硫酸鎂，七水 用于分子生物學(xué)和植物培養(yǎng)級，≥99.0%